CN111424093A

CN111424093A - Kit, device and method for lung cancer diagnosis

Info

Publication number: CN111424093A
Application number: CN202010391310.6A
Authority: CN
Inventors: 赫捷; 高树庚; 高亦博; 郭威
Original assignee: Cancer Hospital and Institute of CAMS and PUMC
Current assignee: Cancer Hospital and Institute of CAMS and PUMC
Priority date: 2020-03-30
Filing date: 2020-05-11
Publication date: 2020-07-17
Anticipated expiration: 2040-05-11
Also published as: CN113604572A; CN114807365A; CN115287351A; CN113881770A; CN111424093B; CN115261465A; CN113604572B; CN113881770B; CN114875142A; CN113667753A; CN113667753B; CN114774540A; CN114875141A; CN113621708B; CN113621708A; CN114875139A; CN114875140A; CN115287350A

Abstract

The invention discloses a kit, a device and a method for lung cancer diagnosis, wherein the kit comprises primers and probes for detecting exosome miRNA markers, and the exosome miRNA markers comprise let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-378h, miR-425-3p, miR-450b-5p, One or more of miR-483-3p, miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706 and miR-885-5 p. The invention provides a noninvasive lung cancer diagnosis method based on exosome, which has high sensitivity and high specificity in lung cancer and provides important values for early diagnosis and recurrence monitoring of lung cancer. It is helpful for preventing and treating lung cancer in our country.

Description

Kit, device and method for lung cancer diagnosis

Technical Field

The invention relates to the field of medical diagnosis, in particular to a diagnostic kit, a device and a method for early lung cancer.

Background

Lung cancer is one of the main cancer species in China and even in the world. According to the latest global cancer statistics in 2018, the incidence and mortality of lung cancer are the first in all cancer species. According to the Chinese tumor registration data of 2019, 390.2 ten thousand cancer cases are newly added in 2015 of China, and the death cases of cancer are about 233.8 ten thousand, wherein lung cancer is the main cause of cancer death in China. Therefore, in order to improve the diagnosis and treatment behaviors of lung cancer in China and improve the prognosis of lung cancer patients, early diagnosis becomes an important problem for diagnosis and treatment of lung cancer.

With the application of low dose helical CT, more and more imaging is shown with lung nodules (single lesions <3cm in the lung interstitium and no associated atelectasis or lymphadenopathy) being discovered. However, not all lung nodules are malignant, and identification of benign and malignant lung nodules has been a difficult point in thoracic surgical clinical diagnosis and treatment. At present, noninvasive detection means such as plasma circulating tumor cells and circulating tumor free DNA are adopted, but the detection sensitivity in early lung cancer diagnosis is not high; therefore, there is a need to develop a highly sensitive method for noninvasive early detection of lung cancer.

Disclosure of Invention

The invention provides an exosome-based reagent, a device and a method for non-invasive early lung cancer diagnosis.

The invention provides a kit for lung cancer diagnosis, which comprises primers and probes for detecting exosome miRNA markers, wherein the exosome miRNA markers comprise let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, One or more of miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706 and miR-885-5 p.

Preferably, the exosome miRNA marker is one or more of miR-3615, miR-502-3p, miR-450b-5p, miR-4746-5p, miR-10a-5p, miR-106b-3p, miR-125a-5p and miR-885-5 p.

Preferably, the exosome miRNA marker is a combination of miR-106-3p, miR-125a-5p and miR-3615.

Preferably, the exosome miRNA marker is a combination of miR-106b-3p, miR-3615 and miR-450b-5 p.

Preferably, the exosome miRNA marker is a combination of miR-106b-3p, miR-125a-5p, miR-3615, miR-450b-5p and miR-885-5 p.

Preferably, the exosome miRNA marker is a combination of miR-106b-3p, miR-10a-3p, miR-125a-5p, miR-3615 and miR-450b-5 p.

Preferably, the source of exosomes comprises one or more of blood, saliva and sputum.

Preferably, the primers and probes comprise:

reverse transcription primers, PCR primers and probes for detecting let-7a-3 p: the reverse transcription primer of the let-7a-3p has a nucleotide sequence shown as a sequence number 1, the PCR upstream primer has a nucleotide sequence shown as a sequence number 2, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 3;

reverse transcription primers, PCR primers and probes for detecting let-7 f-2: the reverse transcription primer of the let-7f-2 has a nucleotide sequence shown as a sequence number 4, the PCR upstream primer has a nucleotide sequence shown as a sequence number 5, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 6;

reverse transcription primers, PCR primers and probes for detecting miR-106b-3 p: the reverse transcription primer of miR-106b-3p has a nucleotide sequence shown as a sequence number 7, the PCR upstream primer has a nucleotide sequence shown as a sequence number 8, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 9;

reverse transcription primers, PCR primers and probes for detecting miR-10a-3 p: the reverse transcription primer of miR-10a-3p has a nucleotide sequence shown as a sequence number 10, the PCR upstream primer has a nucleotide sequence shown as a sequence number 11, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 12;

reverse transcription primers, PCR primers and probes for detecting miR-10a-5 p: the reverse transcription primer of miR-10a-5p has a nucleotide sequence shown as a sequence number 13, the PCR upstream primer has a nucleotide sequence shown as a sequence number 14, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 15;

reverse transcription primers, PCR primers and probes for detecting miR-125a-5 p: the reverse transcription primer of miR-125a-5p has a nucleotide sequence shown as a sequence number 16, the PCR upstream primer has a nucleotide sequence shown as a sequence number 17, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 18;

reverse transcription primers, PCR primers and probes for detecting miR-1294: the reverse transcription primer of miR-1294 has a nucleotide sequence shown as a sequence number 19, the PCR upstream primer has a nucleotide sequence shown as a sequence number 20, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 21;

reverse transcription primers, PCR primers and probes for detecting miR-19a-3 p: the reverse transcription primer of miR-19a-3p has a nucleotide sequence shown as a sequence number 22, the PCR upstream primer has a nucleotide sequence shown as a sequence number 23, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 24;

reverse transcription primers, PCR primers and probes for detecting miR-22-3 p: the reverse transcription primer of miR-22-3p has a nucleotide sequence shown as a sequence number 25, the PCR upstream primer has a nucleotide sequence shown as a sequence number 26, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 27;

reverse transcription primers, PCR primers and probes for detecting miR-29a-3 p: the reverse transcription primer of miR-29a-3p has a nucleotide sequence shown as a sequence number 28, the PCR upstream primer has a nucleotide sequence shown as a sequence number 29, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 30;

reverse transcription primers, PCR primers and probes for detecting miR-30e-5 p: the reverse transcription primer of miR-30e-5p has a nucleotide sequence shown as a sequence number 31, the PCR upstream primer has a nucleotide sequence shown as a sequence number 32, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 33;

reverse transcription primers, PCR primers and probes for detecting miR-3158-3 p: the reverse transcription primer of miR-3158-3p has a nucleotide sequence shown as a sequence number 34, the PCR upstream primer has a nucleotide sequence shown as a sequence number 35, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 36;

reverse transcription primers, PCR primers and probes for detecting miR-330-5 p: the reverse transcription primer of miR-330-5p has a nucleotide sequence shown as a sequence number 37, the PCR upstream primer has a nucleotide sequence shown as a sequence number 38, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 39;

reverse transcription primers, PCR primers and probes for detecting miR-3605-3 p: the reverse transcription primer of miR-3605-3p has a nucleotide sequence shown as a sequence number 40, the PCR upstream primer has a nucleotide sequence shown as a sequence number 41, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 42;

reverse transcription primers, PCR primers and probes for detecting miR-3615: the reverse transcription primer of miR-3615 has a nucleotide sequence shown as a sequence number 43, the PCR upstream primer has a nucleotide sequence shown as a sequence number 44, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 45;

reverse transcription primers, PCR primers and probes for detecting miR-378 h: the reverse transcription primer of miR-378h is a nucleotide sequence shown as a sequence number 46, the PCR upstream primer is a nucleotide sequence shown as a sequence number 47, the downstream primer is a nucleotide sequence shown as a sequence number 80, and the probe is a nucleotide sequence shown as a sequence number 48;

reverse transcription primers, PCR primers and probes for detection of miR-425-3 p: the reverse transcription primer of miR-425-3p has a nucleotide sequence shown as a sequence number 49, the PCR upstream primer has a nucleotide sequence shown as a sequence number 50, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 51;

reverse transcription primers, PCR primers and probes for detecting miR-450b-5 p: the reverse transcription primer of miR-450b-5p has a nucleotide sequence shown as a sequence number 52, the PCR upstream primer has a nucleotide sequence shown as a sequence number 53, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 54;

reverse transcription primers, PCR primers and probes for detecting miR-4746-5 p: the reverse transcription primer of miR-4746-5p has a nucleotide sequence shown as a sequence number 55, the PCR upstream primer has a nucleotide sequence shown as a sequence number 56, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 57;

reverse transcription primers, PCR primers and probes for detecting miR-483-3 p: the reverse transcription primer of miR-483-3p has a nucleotide sequence shown as a sequence number 58, the PCR upstream primer has a nucleotide sequence shown as a sequence number 59, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 60;

reverse transcription primers, PCR primers and probes for detecting miR-502-3 p: the reverse transcription primer of miR-502-3p has a nucleotide sequence shown as a sequence number 61, the PCR upstream primer has a nucleotide sequence shown as a sequence number 62, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 63;

reverse transcription primers, PCR primers and probes for detecting miR-550a-5 p: the reverse transcription primer of miR-550a-5p has a nucleotide sequence shown as a sequence number 64, the PCR upstream primer has a nucleotide sequence shown as a sequence number 65, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 66;

reverse transcription primers, PCR primers and probes for detecting miR-651-5 p: the reverse transcription primer of miR-651-5p has a nucleotide sequence shown as a sequence number 67, the PCR upstream primer has a nucleotide sequence shown as a sequence number 68, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 69;

reverse transcription primers, PCR primers and probes for detecting miR-7706: the reverse transcription primer of miR-7706 is nucleotide sequence as shown in sequence number 70, the PCR upstream primer is nucleotide sequence as shown in sequence number 71, the downstream primer is nucleotide sequence as shown in sequence number 80, and the probe is nucleotide sequence as shown in sequence number 72;

reverse transcription primers, PCR primers and probes for detecting miR-885-5 p: the reverse transcription primer of miR-885-5p has a nucleotide sequence shown as a sequence number 73, the PCR upstream primer has a nucleotide sequence shown as a sequence number 74, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 75.

In another aspect, the invention provides a device for lung cancer diagnosis, which comprises a reagent for detecting exosome miRNA markers, wherein the exosome miRNA markers comprise let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, miR-3605 p, One or more of miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706 and miR-885-5 p.

In another aspect, the invention provides a method for lung cancer diagnosis, comprising detecting the specificity of exosome miRNA markers, wherein the exosome miRNA markers comprise let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, miR-3605 p, One or more of miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706 and miR-885-5 p.

The invention provides a noninvasive lung cancer diagnosis method based on exosome, which has high sensitivity and high specificity in lung cancer and provides important values for early diagnosis and recurrence monitoring of lung cancer. It is helpful for preventing and treating lung cancer in our country. Furthermore, 5 miRNA markers (the combined AUC can reach 0.951, the negative predictive value is 90.32%, the sensitivity is 90.00%, and the specificity is 93.33%) have extremely excellent diagnostic performance.

Drawings

FIG. 1 shows the result of electron microscopy of exosomes.

FIG. 2 is a ROC curve of miR-3615 alone for detecting lung cancer.

FIG. 3 is a ROC curve of miR-502-3p alone for detecting lung cancer.

FIG. 4 is a ROC curve of miR-450b-5p alone for detecting lung cancer.

FIG. 5 is a ROC curve of miR-4746-5p alone for detecting lung cancer.

FIG. 6 is a ROC curve of miR-10a-5p alone for detecting lung cancer.

FIG. 7 is a ROC curve of miR-106-3p + miR-125a-5p + miR-3615 combination for detecting lung cancer.

FIG. 8 is a ROC curve for detecting lung cancer by the combination of miR-106b-3p + miR-3615+ miR-450b-5 p.

FIG. 9 is a ROC curve for detecting lung cancer by the combination of miR-106b-3p + miR-125a-5p + miR-3615+ miR-450b-5p + miR-885-5.

FIG. 10 is a ROC curve for detecting lung cancer by the combination of miR-106b-3p + miR-10a-3p + miR-125a-5p + miR-3615+ miR-450b-5 p.

FIG. 11 is a ROC curve for the combination of miR-106b-3P + miR-10a-5P + miR-125a-5P + miR-3615+ miR-450b-5P to detect lung cancer (reference U6).

Detailed Description

The Extracellular Vesicles (EVs; hereinafter, Vesicles are all referred to as Extracellular Vesicles) refer to vesicular bodies with a double-layer membrane structure, which are shed from cell membranes or secreted by cells, and have diameters of 30-1000nm, and mainly comprise Micro Vesicles (MVs) and exosomes (exosomes), and the Micro Vesicles are small Vesicles shed from cell membranes after cells are activated or damaged. Extracellular vesicles are of great interest in disease diagnosis, particularly exosomes, due to their unique biological characteristics.

The exosome is a membrane vesicle with the particle size of 30-150 nm secreted into the extracellular environment after an intracellular multivesicular body and a cell membrane are fused, is an important medium for intercellular information transfer, and plays an important role in antigen presentation, apoptosis, inflammatory reaction, tumorigenesis development and metastasis processes. It is widely distributed in body fluid, including blood, saliva, urine, milk, hydrothorax and ascites, etc.; contains various inclusion substances such as DNA, RNA, protein and the like, and can be used as noninvasive diagnosis markers of various diseases such as tumors and the like. And miRNA is the most abundant nucleic acid component in exosome, so exosome miRNA has the potential of being used for early diagnosis of lung cancer.

The kit, the device and the method provided by the invention discover one or more miRNA (micro ribonucleic acid) which show significant differential expression in exosome of a patient with early lung cancer as a marker for diagnosing early lung cancer through experimental research.

Significantly differentially expressed mirnas include: let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p and miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706 and miR-885-5 p.

In some preferred embodiments, significantly differentially expressed miRNA molecule markers are used in combination, with the preferred combination being: one or more combinations of miR-3615, miR-502-3p, miR-450b-5p, miR-4746-5p, miR-10a-5p, miR-106b-3p, miR-125a-5p and miR-885-5 p. The combination can provide better basis for early diagnosis of lung cancer and indicate the risk of diseases.

In addition, the kit for lung cancer diagnosis of the invention comprises a primer and a probe for detecting the exosome miRNA marker. The primers and the probes for detecting the exosome miRNA markers comprise:

reverse transcription primers, PCR primers and probes for detecting let-7 f-2: the reverse transcription primer of the let-7f-2 is a nucleotide sequence shown as a sequence number 4, the PCR upstream primer is a nucleotide sequence shown as a sequence number 5, the PCR downstream primer is a nucleotide sequence shown as a sequence number 80, and the probe is a nucleotide sequence shown as a sequence number 6;

reverse transcription primers, PCR primers and probes for detecting miR-106b-3 p: the reverse transcription primer of miR-106b-3p has a nucleotide sequence shown as a sequence number 7, the PCR upstream primer has a nucleotide sequence shown as a sequence number 8, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 9;

reverse transcription primers, PCR primers and probes for detecting miR-10a-3 p: the reverse transcription primer of miR-10a-3p has a nucleotide sequence shown as a sequence number 10, the PCR upstream primer has a nucleotide sequence shown as a sequence number 11, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 12;

reverse transcription primers, PCR primers and probes for detecting miR-10a-5 p: the reverse transcription primer of miR-10a-5p has a nucleotide sequence shown as a sequence number 13, the PCR upstream primer has a nucleotide sequence shown as a sequence number 14, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 15;

reverse transcription primers, PCR primers and probes for detecting miR-125a-5 p: the reverse transcription primer of miR-125a-5p has a nucleotide sequence shown as a sequence number 16, the PCR upstream primer has a nucleotide sequence shown as a sequence number 17, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 18;

reverse transcription primers, PCR primers and probes for detecting miR-1294: the reverse transcription primer of miR-1294 has a nucleotide sequence shown as a sequence number 19, the PCR upstream primer has a nucleotide sequence shown as a sequence number 20, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 21;

reverse transcription primers, PCR primers and probes for detecting miR-19a-3 p: the reverse transcription primer of miR-19a-3p has a nucleotide sequence shown as a sequence number 22, the PCR upstream primer has a nucleotide sequence shown as a sequence number 23, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 24;

reverse transcription primers, PCR primers and probes for detecting miR-22-3 p: the reverse transcription primer of miR-22-3p has a nucleotide sequence shown as a sequence number 25, the PCR upstream primer has a nucleotide sequence shown as a sequence number 26, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 27;

reverse transcription primers, PCR primers and probes for detecting miR-29a-3 p: the reverse transcription primer of miR-29a-3p has a nucleotide sequence shown as a sequence number 28, the PCR upstream primer has a nucleotide sequence shown as a sequence number 29, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 30;

reverse transcription primers, PCR primers and probes for detecting miR-30e-5 p: the reverse transcription primer of miR-30e-5p has a nucleotide sequence shown as a sequence number 31, the PCR upstream primer has a nucleotide sequence shown as a sequence number 32, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 33;

reverse transcription primers, PCR primers and probes for detecting miR-330-5 p: the reverse transcription primer of miR-330-5p has a nucleotide sequence shown as a sequence number 37, the PCR upstream primer has a nucleotide sequence shown as a sequence number 38, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 39;

reverse transcription primers, PCR primers and probes for detecting miR-3605-3 p: the reverse transcription primer of miR-3605-3p has a nucleotide sequence shown as a sequence number 40, the PCR upstream primer has a nucleotide sequence shown as a sequence number 41, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 42;

reverse transcription primers, PCR primers and probes for detection of miR-425-3 p: the reverse transcription primer of miR-425-3p has a nucleotide sequence shown as a sequence number 49, the PCR upstream primer has a nucleotide sequence shown as a sequence number 50, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 51;

reverse transcription primers, PCR primers and probes for detecting miR-450b-5 p: the reverse transcription primer of miR-450b-5p has a nucleotide sequence shown as a sequence number 52, the PCR upstream primer has a nucleotide sequence shown as a sequence number 53, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 54;

reverse transcription primers, PCR primers and probes for detecting miR-4746-5 p: the reverse transcription primer of miR-4746-5p has a nucleotide sequence shown as a sequence number 55, the PCR upstream primer has a nucleotide sequence shown as a sequence number 56, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 57;

reverse transcription primers, PCR primers and probes for detecting miR-502-3 p: the reverse transcription primer of miR-502-3p has a nucleotide sequence shown as a sequence number 61, the PCR upstream primer has a nucleotide sequence shown as a sequence number 62, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 63;

reverse transcription primers, PCR primers and probes for detecting miR-550a-5 p: the reverse transcription primer of miR-550a-5p has a nucleotide sequence shown as a sequence number 64, the PCR upstream primer has a nucleotide sequence shown as a sequence number 65, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 66;

reverse transcription primers, PCR primers and probes for detecting miR-651-5 p: the reverse transcription primer of miR-651-5p has a nucleotide sequence shown as a sequence number 67, the PCR upstream primer has a nucleotide sequence shown as a sequence number 68, the PCR downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 69;

reverse transcription primers, PCR primers and probes for detecting miR-7706: the reverse transcription primer of miR-7706 is nucleotide sequence shown as sequence number 70, the PCR upstream primer is nucleotide sequence shown as sequence number 71, the downstream primer is nucleotide sequence shown as sequence number 80, and the probe is nucleotide sequence shown as sequence number 72;

reverse transcription primers, PCR primers and probes for detecting miR-885-5 p: the reverse transcription primer of miR-885-5p has a nucleotide sequence shown as a sequence number 73, the PCR upstream primer has a nucleotide sequence shown as a sequence number 74, the downstream primer has a nucleotide sequence shown as a sequence number 80, and the probe has a nucleotide sequence shown as a sequence number 75;

reverse transcription primers, PCR primers and probes for detection of internal reference U6: the reverse transcription primer of U6 is shown as a nucleotide sequence in sequence number 78, the PCR upstream primer is shown as a nucleotide sequence in sequence number 76, the PCR downstream primer is shown as a nucleotide sequence in sequence number 78, and the probe is shown as a nucleotide sequence in sequence number 79. The nucleotide sequences of the primers and probes are shown in Table 1.

TABLE 1

Further, the source of exosomes includes one or more of blood, saliva, and sputum.

The kit, the device and the method are suitable for individuals, such as people at high risk of lung cancer, normal individuals and patients after lung cancer operation.

The technical solution of the present invention will be described in detail with reference to the following embodiments, which are a part of the embodiments of the present invention, but not all of them. Other embodiments, which can be derived by one of ordinary skill in the art from the embodiments of the present invention without creative efforts, are within the protection scope of the present invention.

The experimental procedures in the following examples are conventional unless otherwise specified. Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.

In order to screen an exosome marker related to diagnosis of colon lung cancer, 50 cases of early lung cancer patients and 72 cases of controls respectively take blood of not less than 10ml and separate plasma, the blood is used for separating exosomes in the plasma by a classical ultracentrifugation method and extracting RNA, and the obtained RNA is respectively subjected to RNA library construction and sequencing. The data obtained were analyzed bioinformatically to compare differentially expressed RNA in early lung cancer patients and controls. These exosome-derived mRNA level markers can be used for early diagnosis of lung cancer.

Further directed to the method wherein the RNA marker is further analyzed by the following steps: (1) collecting body fluid samples (including blood, sputum and saliva) of individuals to be detected; (2) isolating exosomes in the body fluid; (3) extracting exosome RNA from spkin exogenous cel-miR-39; (4) detecting the expression level of target RNA by using a two-step method; (5) normalizing the expression level of the detection target RNA by using an external reference gene; (6) substituting the normalized gene expression level into a judgment model to obtain an output value; (7) and judging whether the individual to be detected is lung cancer or not according to the output value of the model and the judgment threshold value.

The kit comprises a PCR primer, a probe and a standard substance for detecting the exosome RmiNA marker and a two-step reverse PCR detection system.

Comprises selecting exoginseng Cel-miR-39 or internal reference U6 to quantify target RNA. Wherein the expression level of the marker is calculated by using a quantitative formula 2 delta Ct according to the detection Ct value by using the quantification of the target RNA when the reference is selected. Having obtained the target RNA expression level, the ROC characteristic curve and AUC were used to assess the accuracy of lung cancer detection by single RNA or by combining multiple RNAs.

Example 1 screening of exosome miRNA markers associated with early lung cancer based on high throughput sequencing

In order to screen an exosome marker related to early lung cancer diagnosis, 50 cases of patients 72 and controls with early lung cancer diagnosis are respectively taken, blood is not less than 10ml, plasma is separated, exosome in the plasma is separated by a classical ultracentrifugation method, RNA is extracted by a qiagen miRNeasy mini kit, and the obtained RNA is subjected to small RNA library construction and sequencing. The obtained data were analyzed by bioinformatics, and mirnas differentially expressed in early lung cancer patients and controls were compared to obtain significantly different mirnas as shown in table 2 below. These exosome-derived RNA-level markers can be used for early diagnosis of lung cancer.

TABLE 2

Example 2 fluorescent quantitation PCR platform based miRNA detection system

1. miRNA reverse transcription reaction system

miRNA reverse transcription reagents, enzymes and oligdT were purchased from TAKARA, standards were synthesized from Shanghai Yinxie substrate, and primers with reversed specificity were synthesized by Suzhou Hongyu. A20 ul reverse transcription system was used, as shown in Table 3 below.

TABLE 3

2. PCR reaction system

The PCR reaction mixture was purchased from TAKARA, the upstream primer, the probe, i.e., the universal downstream primer, was synthesized by Honghong, Suzhou, and the fluorescent quantitative PCR instrument was ABI 7500. The PCR reaction system is shown in Table 4 below.

TABLE 4

The PCR procedure was 95 ℃ for 10min, (95 ℃ for 15s, 55 ℃ for 30s) for 15 cycles without fluorescence collection, and (95 ℃ for 15s, 55 ℃ for 30s) for 35 cycles with fluorescence collection.

Example 3 evaluation of early diagnosis and detection effects of lung cancer by taking Ex-seng Cel-miR-39 as reference single marker

1. Sample collection

10ml of blood of control samples of early stage (stage I and stage II) lung nodule lung cancer patients, benign lung nodule patients, healthy persons, etc. diagnosed in hospitals were collected and separated into plasma.

2. Exosome RNA extraction

Plasma exosome separation is carried out by ultracentrifugation or Exosucur of Echobiotech (Beijing Enzekangtai) (the exosome electron microscope identification result is shown in figure 1), miRNA in exosome is extracted from the separated exosome by a Qiagen MIReasy mini kit, RNA concentration and quality are detected by Agilent 2100, and the RNA concentration is recorded.

3. RNA two-step detection system

The two-step method detection system based on the PCR platform miRNA in the embodiment 1 is adopted to detect plasma exosome miRNA of 30 cases and 30 cases of control samples (healthy persons and benign nodules) of early lung cancer patients, detect Ct value of target miRNA, and calculate relative expression according to the Ct value and a relative quantitative formula.

4. Exosome miRNA diagnosis early lung cancer performance assessment

(1) Evaluation of independent detection performance of miR-3615

As shown in FIG. 2, Ct values of miR-3615 were detected for plasma exosomes of 30 patients with early lung cancer and 30 control samples (healthy people and benign lesions), and the copy number of miRNA was obtained according to the Ct values with the external reference Cel-miR-39 as a reference. And calculating the fold change of the relative expression quantity of the combined marker by using a relative quantitative formula value so as to obtain the relative expression quantity of the RNA. And (3) performing t detection analysis on the detection result by adopting R language, wherein pvalue is 0.00058< 0.05, and thus, the exosome miR-3615 is remarkably related to early lung cancer. The AUC of miR-3615 for diagnosing early lung cancer alone is 0.785, the negative predictive value is 85%, the sensitivity is 90%, the specificity is 56.57%, and the potential of a diagnostic marker is realized.

(2) Evaluation of independent detection performance of miR-502-3p

As shown in FIG. 3, Ct values of miR-502-3p were detected for plasma exosomes of 30 patients with early lung cancer and 30 control samples (healthy people and benign lesions), and the copy number of miRNA was obtained according to the Ct values with the external reference Cel-miR-39 as a reference. And calculating the fold change of the relative expression quantity of the combined marker by using a relative quantitative formula value so as to obtain the relative expression quantity of the RNA. And (3) carrying out t-detection analysis on the detection result by adopting an R language, wherein the pvalue is 0.00139 & lt 0.05, and thus, the exosome miR-502-3p is obviously related to early lung cancer. The AUC of miR-502-3p for diagnosing early lung cancer alone is 0.756, the negative predictive value is 68.42%, the sensitivity is 60%, the specificity is 86.67%, and the potential of a diagnostic marker is realized.

(3) Evaluation of independent detection performance of miR-450b-5p

As shown in FIG. 4, Ct values of miR-450b-5p were detected for plasma exosomes of 30 patients with early lung cancer and 30 control samples (healthy people and benign lesions), and the copy number of miRNA was obtained according to the Ct values with the external reference Cel-miR-39 as a reference. And calculating the fold change of the relative expression quantity of the combined marker by using a relative quantitative formula value so as to obtain the relative expression quantity of the RNA. And (3) carrying out t-test analysis on the detection result by adopting R language, wherein the pvalue is 0.00199< -0.05, and thus the exosome miR-450b-5p is obviously related to early lung cancer. The AUC of the miR-450b-5p for diagnosing early lung cancer alone is 0.744, the negative predictive value is 80%, the sensitivity is 86.67%, the specificity is 53.33%, and the potential of a diagnostic marker is realized.

(4) Evaluation of independent detection performance of miR-4746-5p

As shown in FIG. 5, Ct values of miR-4746-5p were detected for plasma exosomes of 30 patients with early lung cancer and 30 control samples (healthy people and benign lesions), and the copy number of miRNA was obtained according to the Ct values with the external reference Cel-miR-39 as a reference. And calculating the fold change of the relative expression quantity of the combined marker by using a relative quantitative formula value so as to obtain the relative expression quantity of the RNA. And (3) performing t-detection analysis on the detection result by adopting R language, wherein pvalue 0.00183 is less than 0.05, and thus the exosome miR-4746-5p is obviously related to early lung cancer. The AUC of miR-4746-5p for diagnosing early lung cancer alone is 0.743, the negative predictive value is 66.67%, the sensitivity is 60%, the specificity is 80%, and the potential of a diagnostic marker is realized.

(5) Evaluation of independent detection performance of miR-10a-5p

As shown in FIG. 6, Ct values of miR-10a-5p were detected for plasma exosomes of 30 patients with early lung cancer and 30 control samples (healthy people and benign lesions), and the copy number of miRNA was obtained according to the Ct values with the external reference Cel-miR-39 as a reference. And calculating the fold change of the relative expression quantity of the combined marker by using a relative quantitative formula value so as to obtain the relative expression quantity of the RNA. And (3) carrying out t-test analysis on the detection result by adopting R language, wherein pvalue 0.00183 is less than 0.05, and thus the exosome miR-10a-5p is obviously related to early lung cancer. The AUC of the miR-10a-5p for diagnosing early lung cancer alone is 0.73, the negative predictive value is 77.27%, the sensitivity is 83.33%, the specificity is 56.67%, and the potential of a diagnostic marker is realized.

(6) Assessment of the Performance of other markers significantly associated with early Lung cancer

Other significantly related miRNA performance assessments are shown in table 5 below.

TABLE 5

From the data shown in table 5, it can be seen that the mirnas described in the table all have the potential for diagnostic markers.

Example 4 evaluation of the Effect of early diagnosis and detection of Lung cancer by combination of multiple markers with exogenous control Cel-miR-39 as reference

1. Three marker combination performance evaluation

The relative expression of each miRNA was calculated according to the method in example 3, and the three marker combinations were trained using logistic regression, and the combinations with AUC of the three marker combinations above 0.85 were obtained as shown in table 6 below. Wherein the combination of miR-106-3p + miR-125a-5p + miR-3615, miR-106b-3p + miR-3615+ miR-450b-5p and the like has optimal performance, the AUC is 0.887 and 0.881 respectively, and the AUC curves are respectively shown in figure 7 and figure 8.

TABLE 6

2. Five marker combination performance evaluation

Relative expression of each miRNA was calculated according to the method in example 3, and five marker combinations were trained using logistic regression, and the combinations with AUC of the five marker combinations above 0.93 were obtained as shown in table 7 below. Wherein the combination performance of the miR-106b-3p + miR-125a-5p + miR-3615+ miR-450b-5p + miR-885-5p, the miR-106b-3p + miR-10a-3p + miR-125a-5p + miR-3615+ miR-450b-5p and the like is optimal, the AUCs are respectively 0.951 and 0.948, and the AUC curves are respectively shown in figure 9 and figure 10.

TABLE 7

Example 5 evaluation of the Effect of the detection of early diagnosis of Lung cancer by combination of multiple markers with reference to internal reference U6

The relative expression level of each miRNA with U6 as a reference was calculated according to the method in example 3, and five marker combinations were trained using logistic regression, and the combinations with AUC of 85 or more of the five marker combinations were obtained as shown in table 8 below. Wherein the combination of the mmiR-106b-3P + miR-10a-5P + miR-125a-5P + miR-3615+ miR-450b-5P has the optimal performance, the AUC is 0.864, and the AUC curves are respectively shown in figure 11.

TABLE 8

The data show that the lung cancer detection method based on the exosome miRNA marker can realize noninvasive diagnosis of lung cancer, provides important values for early diagnosis and recurrence monitoring of lung cancer, and is of great help to prevention and treatment of lung cancer in China. Among them, 5 miRNA markers (the combined AUC can reach up to 0.951, the negative predictive value is 90.32%, the sensitivity is 90.00%, and the specificity is 93.33%) have extremely superior diagnostic performance.

The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, to thereby enable others skilled in the art to best utilize the invention. The invention is limited only by the claims and their full scope and equivalents.

Sequence listing

<110> tumor hospital of Chinese medical science institute

<120> kit, device and method for lung cancer diagnosis

<130>200001

<160>80

<170>SIPOSequenceListing 1.0

<210>1

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>1

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgaaaga 50

<210>2

<211>21

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>2

cgcgccctat acaatctact g 21

<210>3

<211>24

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>3

tcgcactgga tacgacgaaa gaca 24

<210>4

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>4

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacggaaag 50

<210>5

<211>21

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>5

agcgcctata cagtctactg t 21

<210>6

<211>24

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>6

tcgcactgga tacgacggaa agac 24

<210>7

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>7

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgcagca 50

<210>8

<211>17

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>8

accgcactgt gggtact 17

<210>9

<211>22

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>9

tcgcactgga tacgacgcag ca 22

<210>10

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>10

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactattcc 50

<210>11

<211>21

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>11

acgcgcaaat tcgtatctag g 21

<210>12

<211>25

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>12

ttcgcactgg atacgactat tcccc 25

<210>13

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>13

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgaccacaaa 50

<210>14

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>14

cgctaccctg tagatccgaa 20

<210>15

<211>25

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>15

ttcgcactgg atacgaccac aaatt 25

<210>16

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>16

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactcacag 50

<210>17

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>17

cgtccctgag accctttaac 20

<210>18

<211>24

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>18

tcgcactgga tacgactcac aggt 24

<210>19

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>19

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacagacaa 50

<210>20

<211>19

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>20

tgctgtgagg ttggcattg 19

<210>21

<211>24

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>21

ttcgcactgg atacgacaga caac 24

<210>22

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>22

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactcagtt 50

<210>23

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>23

cgctgtgcaa atctatgcaa 20

<210>24

<211>25

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>24

tcgcactgga tacgactcag ttttg 25

<210>25

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>25

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacacagtt 50

<210>26

<211>19

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>26

accaagctgc cagttgaag 19

<210>27

<211>24

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>27

tcgcactgga tacgacacag ttct 24

<210>28

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>28

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactaaccg 50

<210>29

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>29

cccgtagcac catctgaaat 20

<210>30

<211>24

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>30

ttcgcactgg atacgactaa ccga 24

<210>31

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>31

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgaccttcca 50

<210>32

<211>21

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>32

accgctgtaa acatccttga c 21

<210>33

<211>22

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>33

tcgcactgga tacgaccttc ca 22

<210>34

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>34

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgtcctg 50

<210>35

<211>19

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>35

acgaagggct tcctctctg 19

<210>36

<211>22

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>36

tcgcactgga tacgacgtcc tg 22

<210>37

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>37

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgcctaa 50

<210>38

<211>18

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>38

actctctggg cctgtgtc 18

<210>39

<211>22

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>39

tcgcactgga tacgacgcct aa 22

<210>40

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>40

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacctagag 50

<210>41

<211>19

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>41

agcctccgtg ttacctgtc 19

<210>42

<211>24

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>42

tcgcactgga tacgacctag agga 24

<210>43

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>43

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgagccg 50

<210>44

<211>17

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>44

cctctctcgg ctcctcg 17

<210>45

<211>22

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>45

tcgcactgga tacgacgagc cg 22

<210>46

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>46

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacccatct 50

<210>47

<211>18

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>47

gcgactggac ttggtgtc 18

<210>48

<211>23

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>48

tcgcactgga tacgacccat ctg 23

<210>49

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>49

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgggcgg 50

<210>50

<211>19

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>50

agcatcggga atgtcgtgt 19

<210>51

<211>21

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>51

tcgcactgga tacgacgggc g 21

<210>52

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>52

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactattca 50

<210>53

<211>21

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>53

tccgcttttg caatatgttc c 21

<210>54

<211>26

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>54

ttcgcactgg atacgactat tcagga 26

<210>55

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>55

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactctgca 50

<210>56

<211>17

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>56

ccggtcccag gagaacc 17

<210>57

<211>22

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>57

tcgcactgga tacgactctg ca 22

<210>58

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>58

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacaagacg 50

<210>59

<211>18

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>59

cgctcactcc tctcctcc 18

<210>60

<211>23

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>60

tcgcactgga tacgacaaga cgg 23

<210>61

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>61

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactgaatc 50

<210>62

<211>18

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>62

acaatgcacc tgggcaag 18

<210>63

<211>25

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>63

ttcgcactgg atacgactga atcct 25

<210>64

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>64

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgggctc 50

<210>65

<211>19

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>65

cgagtgcctg agggagtaa 19

<210>66

<211>22

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>66

tcgcactgga tacgacgggc tc 22

<210>67

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>67

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgaccaaaag 50

<210>68

<211>21

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>68

cgcgctttag gataagcttg a 21

<210>69

<211>25

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>69

ttcgcactgg atacgaccaa aagtc 25

<210>70

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>70

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactctcgg 50

<210>71

<211>17

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>71

tgaagcgcct gtgctct 17

<210>72

<211>23

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>72

tcgcactgga tacgactctc ggc 23

<210>73

<211>50

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>73

gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacagaggc 50

<210>74

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>74

acgctccatt acactaccct 20

<210>75

<211>22

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>75

tcgcactgga tacgacagag gc 22

<210>76

<211>17

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>76

ctcgcttcgg cagcaca 17

<210>77

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>77

aacgcttcac gaatttgcgt 20

<210>78

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>78

aacgcttcac gaatttgcgt 20

<210>79

<211>25

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>79

agaagattag catggcccct gcgca 25

<210>80

<211>16

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>80

gtgcagggtc cgaggt 16

Claims

1. A kit for lung cancer diagnosis is characterized by comprising primers and probes for detecting exosome miRNA markers, wherein the exosome miRNA markers comprise let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, One or more of miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706 and miR-885-5 p.

2. The kit according to claim 1, wherein the exosome miRNA marker is one or more of miR-3615, miR-502-3p, miR-450b-5p, miR-4746-5p, miR-10a-5p, miR-106b-3p, miR-125a-5p and miR-885-5p in combination.

3. The kit according to claim 1, wherein the exosome miRNA marker is a combination of miR-106-3p, miR-125a-5p and miR-3615.

4. The kit according to claim 1, wherein the exosome miRNA marker is a combination of miR-106b-3p, miR-3615 and miR-450b-5 p.

5. The kit according to claim 1, wherein the exosome miRNA marker is a combination of five of miR-106b-3p, miR-125a-5p, miR-3615, miR-450b-5p, miR-885-5 p.

6. The kit according to claim 1, wherein the exosome miRNA marker is a combination of five of miR-106b-3p, miR-10a-3p, miR-125a-5p, miR-3615 and miR-450b-5 p.

7. The kit of claim 1, wherein the source of exosomes comprises one or more of blood, saliva, and sputum.

8. The kit of claim 1, wherein the primers and probes comprise:

a reverse transcription primer for detecting miR-502-3p, a nucleotide sequence shown by PCR, a downstream primer is a nucleotide sequence shown by a sequence number 80, and a probe is a nucleotide sequence shown by a sequence number 66;

9. A device for lung cancer diagnosis, which comprises a reagent for detecting exosome miRNA markers, wherein the exosome miRNA markers comprise let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, miR-3605 p, One or more of miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706 and miR-885-5 p.

10. A method for lung cancer diagnosis is characterized by comprising the step of detecting the specificity of exosome miRNA markers, wherein the exosome miRNA markers comprise let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, miR-3605 p, One or more of miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706 and miR-885-5 p.